Efficacy and Safety of Fremanezumab in Episodic Migraine: A Systematic Review and Meta-analysis
Authors:
- Taha IbrahimTITaha Ibrahim
- Muhammad BurhanMBMuhammad Burhan
- Shaheer Bin ShafiqSSShaheer Bin Shafiq
- Ali WajahatAWAli Wajahat
- Owais SanaullahOSOwais Sanaullah
- Muhammad Hanzalah AtifMAMuhammad Hanzalah Atif
- Ghulam Taha KhanGKGhulam Taha Khan
- Muhammad AnzarMAMuhammad Anzar
- Ammad UddinAUAmmad Uddin
- Jawaria IbrahimJIJawaria Ibrahim
- Muhammad Ahmed ZahoorMZMuhammad Ahmed Zahoor
- Ibrahim Nagmeldin HassanIHIbrahim Nagmeldin Hassan
- 9 September 2026
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
Abstract
Background: Fremanezumab, a calcitonin gene-related peptide monoclonal antibody, is approved for migraine prevention, yet evidence specific to episodic migraine remains limited. We synthesized randomized evidence on its efficacy and safety. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420261385104), we systematically searched PubMed, Embase, and Scopus from inception to June 5, 2026, for placebo-controlled randomized controlled trials (RCTs) evaluating fremanezumab for episodic migraine prevention. Primary outcomes were the ≥50% responder rate and change in monthly migraine days. Random-effects meta-analyses were performed, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Four RCTs including 1764 participants were included. Fremanezumab significantly increased the ≥50% responder rate (risk ratio: 1.81, 95% CI: 1.53-2.15) and reduced monthly migraine days (mean difference: −1.98, 95% CI: −2.93 to −1.03), headache days, acute medication-use days, and migraine-related disability. Overall safety was comparable to placebo, with no significant differences in treatment-emergent adverse events, serious adverse events, or treatment discontinuations; injection-site induration occurred more frequently with fremanezumab. Relevance to Patient Care and Clinical Practice: This meta-analysis strengthens the evidence supporting fremanezumab as an effective and generally well-tolerated preventive therapy for episodic migraine. The demonstrated reductions in migraine frequency, disability, and acute medication use, together with flexible monthly and quarterly dosing, support its use in appropriately selected patients and may facilitate individualized treatment decisions by clinicians and pharmacists. Although the inclusion of pediatric data expands the current evidence base, these findings should be interpreted cautiously because they are derived from a single randomized trial. Conclusion: Fremanezumab is an effective and generally well-tolerated preventive treatment for episodic migraine. Evidence is robust in adults, whereas pediatric findings remain preliminary and warrant confirmation in future randomized trials.Keywords
This publication has 46 references indexed in Scilit:
- Review: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic MigraineCurrent Pain and Headache Reports, 2025
- Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 StudyNeurology and Therapy, 2024
- Acute Treatment of Migraine: Expert Consensus Statements from the United Arab Emirates (UAE)Neurology and Therapy, 2024
- Migraine: from pathophysiology to treatmentJournal of Neurology, 2023
- Efficacy, Safety, and Acceptability of Pharmacologic Treatments for Pediatric Migraine ProphylaxisJAMA Pediatrics, 2020
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trialThe Lancet, 2019
- Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and SafetyDrugs, 2019
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic MigraineJAMA, 2018
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyThe Lancet Neurology, 2015
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011